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Abstract
Background: Inherited peripheral neuropathy (IPN) is a clinically and genetically heterogeneous group of disorders
with more than 90 genes associated with the different subtypes. Sequential gene screening is gradually being
replaced by next generation sequencing (NGS) applications.
Methods: We designed and validated a targeted NGS panel assay including 56 genes associated with known causes of
IPN. We report our findings following NGS panel testing of 448 patients with different types of clinically-suspected IPN.
Results: Genetic diagnosis was achieved in 137 patients (31 %) and involved 195 pathogenic variants in 31 genes.
93 patients had pathogenic variants in genes where a resulting phenotype follows dominant inheritance, 32 in genes
where this would follow recessive inheritance, and 12 presented with X-linked disease.
Almost half of the diagnosed patients (64) had a pathogenic variant either in genes not previously available for routine
diagnostic testing in a UK laboratory (50 patients) or in genes whose primary clinical association was not IPN (14).
Seven patients had a pathogenic variant in a gene not hitherto indicated from their phenotype and three patients
had more than one pathogenic variant, explaining their complex phenotype and providing information essential for
accurate prediction of recurrence risks.
Conclusions: Our results demonstrate that targeted gene panel testing is an unbiased approach which overcomes
the limitations imposed by limited existing knowledge for rare genes, reveals high heterogeneity, and provides high
diagnostic yield. It is therefore a highly efficient and cost effective tool for achieving a genetic diagnosis for IPN.
Background
Inherited peripheral neuropathy (IPN) is the most common
group of inherited neurological disorders with an estimated
prevalence of 1 in 2500 individuals [1]. It is clinically and
genetically heterogeneous; with over 90 genes and loci
implicated in the normal function of the myelinated axons
of the peripheral nervous system. Onset is typically in the
first or second decade, but there are congenital and infant-
ile onset forms of the disease, as well as late onset adult
forms. The classical clinical phenotype may manifest as
distal limb muscle wasting and weakness, mild to moderate
sensory loss, abnormalities of deep tendon reflexes and foot
deformities (pes cavus and hammer toes). Hearing loss, or
respiratory impairment resulting from phrenic nerve
involvement, may also be characteristic in some forms.
IPN classification is based on clinical phenotype,
mode of inheritance, age of onset, electrophysiological
studies and causal mutation. The main subtypes include
hereditary motor and sensory neuropathy (HMSN), ty-
pically known as Charcot-Marie-Tooth disease (CMT);
hereditary sensory and autonomic neuropathy (HSAN)
also known as hereditary sensory neuropathy; hereditary
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motor neuropathy (HMN), also known as distal hereditary
motor neuropathy, and hereditary neuropathy with liability
to pressure palsy (HNPP).
CMT is the phenotype with the widest genetic hetero-
geneity. Nerve conduction velocity studies (NCV) subdiv-
ide CMT into type 1 (CMT1), a demyelinating form with
median or ulnar motor NCV <38 m/s; type 2 (CMT2), an
axonal form with NCV >38 m/s, and an intermediate
form with both demyelinating and axonal features. Inher-
itance modes include autosomal dominant (AD), auto-
somal recessive (AR) and X-linked (XL). A single gene
may be implicated in different phenotypes and present
with different modes of inheritance, presenting a challenge
to diagnose patients with specific types of IPN [2, 3].
Following the exclusion of a 1.5 Mb duplication at
17p11.2 including the PMP22 gene as the most common
cause of CMT1, the traditional strategy for genetic testing
consisted of sequential sequencing of individual genes,
selected according to the patient’s clinical presentation
and family history. This strategy, alongside the cost of
serial testing and the limited breadth of genes available for
testing, resulted in a low diagnostic yield.
Since the cost of next generation sequencing (NGS)
has been decreasing dramatically over the last few years,
this technology has found numerous applications in the
diagnosis of heterogeneous disorders, including IPN.
Whole genome sequencing (WGS) and whole exome
sequencing (WES) have identified new genetic causes for
many conditions, as demonstrated for IPN by the identi-
fication of SH3TC2 as a cause of autosomal recessive
CMT1 [4] and DYNC1H1 as a new genetic cause for
autosomal dominant CMT2 [5].
The targeted panel approach, which restricts analysis to
genes known to be implicated in a particular phenotype has
also been also successfully applied to IPN. Choi et al.
applied WES to a series of unrelated individuals with CMT
and restricted analysis to genes already known to be causes
of IPN [6]. WGS and WES, however, generate a huge
amount of data. Management and storage of this data can
present a challenge in a clinical diagnostic environment.
We designed and validated a targeted NGS panel assay
including 56 genes associated with known causes of in-
herited neuropathy and evaluated this approach for the
diagnosis of IPN. The results of the pilot project were
submitted as a gene dossier to the UK Genetic Testing
Network (UKGTN) [7]. This received approval in January
2013 and the diagnostic service was launched in July 2013.
We present and summarise the results of 448 patients
reported in the first 18 months of this diagnostic service.
Methods
Patients
Blood or DNA samples from patients referred by neurol-
ogists and clinical geneticists were accepted for testing
when the UKGTN approval criteria were met. These
criteria are listed below:
a. ‘Idiopathic’ peripheral neuropathy diagnosed by
clinical presentation with progressive weakness in
hands/wrists and/or feet/ankles and/or associated
pes cavus or finger flexion contractures and/or
peripheral sensory loss
b. Supportive nerve conduction test result (defining
type I or II according to NCV)
c. Absence of other non-genetic causes (alcohol, B12
deficiency, diabetes, trauma)
d. No associated CNS involvement
The referring clinicians were also asked to indicated the
suspected mode of inheritance and provide a recent clin-
ical letter with further details of the clinical phenotype. A
small number of samples were accepted for testing from
patients not strictly meeting these criteria, after discussion
with the individual requesting clinician.
From July 2013 to December 2014, DNA samples from
448 unrelated probands with suspected IPN were tested
and reported; a significant proportion of these patients
had previously tested negative for the common causes of
IPN.
Two hundred ninety nine patients were referred by
neurologists (67 %) and 149 patients (33 %) by clinical
geneticists. Approximately one third of the patients were
under 18 years of age at referral (135 patients, 30 %).
Informed consent for IPN multi-gene panel testing was
obtained from patients or their parents/legal guardians by
the requesting clinician. The decision to request this test
was made by each clinician according to their local ethical
guidelines.
This diagnostic test has been assessed for validity, utility
and socio-legal/ethical implications in the process of ratifi-
cation by the UKGTN and UK NHS commissioners, and
was undertaken in an accredited UK NHS Laboratory.
Data presented pertains only to results of routine diagnos-
tic testing; therefore this study was not subject to ethical
approval.
Targeted capture
Genes were selected following extensive searches of the
literature and locus specific databases [8, 9] to ensure their
clinical validity and utility. Two additional genes flanking
PMP22 that are commonly involved in the 1.5 Mb recip-
rocal deletion/duplication event occurring at 17p11.2 [10]
were included, to assist in the copy number assessment of
this region (COX10, TEKT3). All the genes had a disease
OMIM (Online Mendelian Inheritance in Man) entry
related to a subtype of peripheral neuropathy. Table 1
details the 56 genes included in the assay.
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Table 1 Genes included in IPN NGS panel, with associated phenotype and inheritance pattern
GENE OMIM Locus CMT1 CMT2 HMN HS(A)N OMIM Inheritance
AARS 601065 16q22 CMT 2N 613287 AD
ARHGEF10 608136 8p23 Slowed NCV; hypomyelination 608236 AD
ATL1 606439 14q11-q21 HSN 1D 613708 AD
ATP7A 300011 Xq12-q13 dSMAX3 300489 XL
BAG3 603883 10q26.11 Myopathy; myofibrillar, BAG-3 related 612954 AD
BSCL2 606158 11q12.3 HMN 5 600794 AD
CCT5 610150 5p15.2 HSN with spastic paraplegia 256840 AR
CTDP1 604927 18q23 CCFDN: Congenital cataracts, facial dysmorphism, neuropathy 604168 AR
DCTN1 601143 2p13.1 HMN 7B 607641 AD
DNM2 602378 19p13.2 CMT DI B 606482 AD
CMT 2 M
DYNC1H1 600112 14q32.31 CMT 2O SMA-LED 614228/158600 AD
EGR2 129010 10q21.1-q22.1 CMT 1D 607678 AD
CMT 4E CHN 605253 AD
DSS 145900 AR
FAM134B 613114 5p15.1 HSAN 2B 613115 AR
FGD4 611104 12p11.21 CMT 4H 609311 AR
FIG4 609390 6q21 CMT 4J 611228 AR
GAN 605379 16q23.2 Giant Axonal Neuropathy 1 256850 AR
GARS 600287 21q22.11 CMT 2D HMN 5 601472/600794 AD
GDAP1 606598 8q21 CMTA RI 608340 AR
CMT 4A 214400 AR
CMT 2H 607706 AR
CMT 2K 607831 AD
GJB1 304040 Xq13.1 CMT X1 302800 XL
HOXD10 142984 2q31.1 HMSN with Congenital vertical talus 192950 AD
HSPB1 602195 7q11 CMT 2F HMN 2B 606595/608634 AD
HSPB3 604624 5q11.2 HMN 2C 613376 AD
HSPB8 608014 12q24 CMT 2L HMN 2A 608673/158590 AD
IGHMBP2 600502 11q13.3 HMN 6 604320 AR
IKBKAP 603722 9q31.3 HSAN 3 223900 AR
KARS 601421 16q23.1 CMT RI B 613641 AR
KIF1B 605995 1p36.22 CMT 2A1 118210 AD
LITAF 603795 16p13.3-p12 CMT 1C 601098 AD
LMNA 150330 1q22 CMT 2B1 605588 AR
LRSAM1 610933 9q33.3 CMT 2P 614436 AD/AR
MED25 610197 19q33.13 CMT 2B2 605589 AR
MFN2 608507 1p35-36 CMT 2A2 609260 AD
HMSN6 601152
MPZ 159440 1q22 CMT 1B 118220 AD
CHN 605253
CMT DI D 607791
CMT 2I 607677
CMT 2J 607736
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A custom SureSelect (Agilent Technologies) solution-
based oligonucleotide target capture assay was designed
using the web-based tool eArray (version 7.7). Regions
of interest (ROI) were designed to encompass coding
regions of all alternate transcripts for each gene. 5’ and
3’ untranslated regions and non-coding exons were also
included. Promoter sites were included for GJB1 and
PMP22, and also part of MPZ intron 1 [11]. Each ROI
included 20 base pairs (bp) upstream and 10 bp down-
stream of the coding exon to capture canonical splicing
donor and acceptor sites.
Library preparation and sequencing
Genomic DNA was extracted from whole blood using
the Puregene protocol (Gentra Systems Incorporated),
EZ1 DNA Blood kit (Qiagen) or a standard phenol-
chloroform extraction. We also received DNA samples
extracted in other laboratories. A Qubit 2.0 Fluorometer
(Life Technologies) was used to quantify double stranded
DNA concentration in genomic DNA samples. Sequencing
libraries were prepared according to the manufacturer’s
standard protocol; SureSelectXT Target Enrichment Sys-
tem for Illumina Paired-End Sequencing Library Illumina
HiSeq and MiSeq Multiplexed Sequencing Platforms Ver-
sion 1.5, November 2012. Genomic DNA was sheared
to a median size of 200 bp using the Bioruptor NGS
sonicator (Diagenode). Fragment size was assessed using
the Tapestation 2100 Bioanalyzer (Agilent Technologies).
Sequencing was performed on a MiSeq instrument (Illu-
mina) using Version 2 reagents, 2x150 paired-end reads in
batches of 16 patients’ samples.
Data analysis was performed using an open source in-
house pipeline (alignment: BWA; alignment modification
and variant calling: GATKv2; variant annotation: Annovar)
with hg19 human genome as a reference, and followed the
Association of Clinical Genetics Science (ACGS) Practice
Guidelines [12]. Viewing of variants and recording of
classification evidence was facilitated using Geneticist
Table 1 Genes included in IPN NGS panel, with associated phenotype and inheritance pattern (Continued)
MTMR2 603557 11q21 CMT 4B1 601382 AR
NDRG1 605262 8q24.22 CMT 4D 601455 AR
NEFL 162280 8p21 CMT 1F CMT 2E 607734/607684 AD
NGFB 162030 1q13.2 HSAN 5, absence of pain 608654 AR
NTRK1 191315 1q23.1 HSAN 4; anhidrosis, insensitivity
to pain
256800 AR
PLEKHG5 611101 1p36.31 CMT RIC dSMA 4 615376/611067 AR
PMP22 601097 17p11.2 CMT 1A 118220 AD
HNPP 162500 AD
CMT 1E 118300 AD
DSS 145900 AR
PRPS1 311850 Xq22.3 CMT X5 311070 XL D/R
PRX 605725 19q13.1-q13.2 CMT 4F/DSS 145900 AR
RAB7A 602298 3q21.3 CMT 2B HSN 600882 AD
REEP1 609139 2p11.2 HMN5B 614751 AD
SBF2 607697 11p15.4 CMT 4B2 604563 AR
SCN9A 603415 2q24.3 Absence of pain 243000 AR
Small fibre neuropathy 133020 AD
SEPT9 604061 17q25.2-q25.3 Hereditary neuralgic amyotrophy, HNS, HNA & dysmorphic features 162100 AD
SH3TC2 608206 5q32 CMT 4C 601596 AR
SLC12A6 604878 15q14 PN with agenesis of the corpus callosum 218000 AR
SOX10 602229 22q13.1 PCWH syndrome 609136 AD
SPTLC1 605712 9q22.1-q22.3 HSAN 1 162400 AD
SPTLC2 605713 14q24.3 HSAN 1C 613640 AD
TDP1 607198 14q32.11 Spinocerebellar ataxia, with axonal neuropathy 607250 AR
TRPV4 605427 12q24.1 CMT 2C 606071 AD
WNK1 605232 12p13.33 HSAN 2A 201300 AR
YARS 603623 1p13.1 CMT DI C 608323 AD
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Assistant software (Soft Genetics). Copy number enumer-
ation was performed for the 17p11.2 region using the
CONTRA tool as a component of the analysis pipeline
[13]. This was necessary to ensure that the most frequent
cause of CMT1/HNPP (and therefore a positive genetic
diagnosis) would not be missed if a patient had not been
pre-screened for PMP22 dosage, for reasons of clinical
oversight, or an atypical clinical presentation.
The assay was validated using genomic DNA samples
from nine patients previously tested in our laboratory;
six of these had single nucleotide variants (SNVs) in six
different genes (a total of 26 SNVs),previously identified
by Sanger sequencing. A further three had the classical
deletion or duplication of PMP22, identified previously
by MLPA dosage analysis. All 26 SNV occurrences and
the PMP22 copy number variants (CNVs) were con-
firmed using this assay. Using 95 % confidence intervals
for the binomial distribution, the sensitivity of this assay
was determined to be between 87 and 100 % [14]. To
date, all of the (410) variants detected by NGS and
followed up by subsequent Sanger sequencing have been
confirmed as true positives. Due to lack of CNV positive
controls for genes other than PMP22, the analysis pipe-
line has not been validated as capable of CNV detection
automatically. Visual checking of CONTRA data is under-
taken when one pathogenic variant is detected in a re-
cessive gene. Small insertions and deletions have been
detected and confirmed, ranging from 2 bp to whole gene
deletions; however this does not exclude the possibility
that there are other CNVs present that were not detected.
The report of results states clearly that the test has not
excluded copy number variation in the genes examined.
Variant filtering and classification
Variants were managed using Genetic Assistant (SoftGe-
netics). Classification followed the Association of Clinical
Genetics Science Practice Guidelines [15], and all variants
were classified into five pathogenicity groups. Table 2 de-
tails the criteria applied to classify variants (Class 1: clearly
not pathogenic; Class 2: unlikely to be pathogenic; Class 3:
unknown significance; Class 4: likely to be pathogenic;
Class 5; clearly pathogenic). Variants were filtered accord-
ing to their frequency; assessment included comparison of
frequency data from the database dbSNP (version 142)
[16] and the Exome Variant Server (version 6500) [17]. All
variants with frequency above 3 % were considered as
clearly not pathogenic (Class 1). The remaining variants
were further investigated for their clinical significance.
Literature searches, the IPNMDB database [8] and our
local laboratory database were interrogated. In silico ana-
lysis was assisted by AlamutVisual (Interactive Biosoftware),
which incorporates multiple amino acid substitution and
splice-prediction tools.
Variants classified as pathogenic, likely pathogenic or of
uncertain clinical significance were confirmed by Sanger
sequencing and were detailed within the report of results.
Candidate pathogenic CNVs were confirmed by MLPA
analysis either using a commercially available probe mix
(MRC Holland), or alternatively by designing bespoke
MLPA probes to target the gene of interest, combining
these with the MRC Holland P300-A2 reference probe
mix. Bespoke MLPA probes were designed using the
online tool MAPD [18].
For patients without candidate pathogenic variants,
one unique variant was selected and confirmed by Sanger
sequencing to ensure the correct identification of all
samples in the batch.
Results and discussion
Analysis of the data demonstrated high read depth and
target coverage. On average, 99.81 % of the targeted region
was covered to a minimum of 30x reads, and 99.86 % to a
minimum of 15x. The mean depth of coverage was 537x
reads.
A total of 56,000 variants were detected in the 448 pa-
tients. Of those, 1830 variants had prevalence less than
3 % in dbSNP (version 142) or in Exome Variant Server
(version 6500). These variants were individually assessed
and classified according to the ACGS guidelines [14].
Gene spectrum in the diagnosis
A total of 195 variants in 31 genes provided a genetic
diagnosis for 137 patients (diagnostic yield 31 %). Of
these, 107 variants were previously reported in the litera-
ture as pathogenic with supporting evidence (Additional
file 1: Table S1). The remaining 88 variants were novel
and were classified as likely pathogenic (class 4) based
on conservation, in silico predictions, phenotype com-
patibility and in several cases family studies (Additional
file 2: Table S2). 215 variants were classified as of un-
certain clinical significance (Additional file 3: Table S3)
and the remaining 1420 variants were assessed as
unlikely pathogenic (class 2) or clearly not pathogenic
(class 1).
Fifty patients had pathogenic variants in genes not
previously available for genetic testing in a diagnostic
setting in the UK, including six with variants in regions
of the DYNC1H1 gene not previously screened due to its
large size; another 14 had pathogenic variants in genes
where testing was previously available but did not fea-
ture in the regular IPN diagnostic strategy (Table 3).
Diagnostic yield in the different IPN subtypes
The patients were grouped into a phenotypic subtype
according to the information on the clinical proforma
provided. Table 3 presents the positive diagnostic yield
achieved in detail. The diagnostic yield was highest for
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patients with demyelinating neuropathy (41/101, 41 %).
This cohort included CMT1 patients in whom a 17
p11.2 PMP22 copy number variant had previously been
excluded. The group of the patients with axonal neur-
opathy had a diagnostic yield of 35.5 % (54/152), similar
to the group of patients with mixed neuropathy (36 %,
8/22). The diagnostic yield in patients with HMN was
26 % (24/91) and for HSN 20 % (5/25). Only 5/57
patients received a genetic diagnosis (9 %) in the
group with the complex phenotypes. This group included
patients with multisystem disorders, where neuropathy
was not the primary cause of disease, and UKGTN criteria
were not strictly met; however testing was performed as
the clinical teams felt it would be beneficial.
The majority (93/137, 68 %) of the genetically diag-
nosed patients had an autosomal dominant form of
neuropathy, while 12 patients presented with X-linked
disease (9 %). It has been previously estimated that in
Northern Europe and North American populations,
approximately 90 % of cases of CMT are either auto-
somal dominant or X-linked [3, 19]. Autosomal recessive
disease is estimated to account for significantly less,
although in populations with a high rate of consanguin-
eous marriages, autosomal recessive forms can account
for up to 40 % [20]. We identified 32 patients with reces-
sive aetiology, representing almost one quarter of our
positive cases (23 %). The age of the patients with reces-
sive neuropathy ranged from 3 to 68 years at the time of
diagnosis. Fifteen patients were under 18 years of age
(47 %) while 17 were adults (53 %). Evidently autosomal
recessive peripheral neuropathy is not exclusively associ-
ated with very early onset, severe progressive disease.
Table 2 Criteria applied in the classification of variants
Class Pathogenicity Criteria
5 Clearly pathogenic 1. Reported in the literature as pathogenic with supporting evidence; multiple independent cases, pedigree
segregation studies and/or functional analysis AND
2. Phenotype and inheritance pattern in patient correlates with the gene
4 Likely to be
pathogenic
1. Not described in the literature, or weak evidence for pathogenicity in published literature; no segregation
or functional analysis available AND
2. Phenotype and inheritance pattern in patient correlates with the gene AND
3. Location of variant in gene and pathogenic mechanism are compatible with previously described
pathogenic variants in the gene AND
4. Minor allele frequency (MAF) is <1 % in dbSNP (v142) and <1 % in Exome Variant Server (EVS, v6500) AND
5. a) Missense variant; conserved amino acid, Polyphen 2 (HumVar) and SIFT concur in predicting deleterious
effect or three or more of five splice prediction toolsa return >10 % difference in splice site prediction value
between wild type and variant OR
b) Frameshift or nonsense variant; where expected mechanism is loss of function OR
c) Synonymous or intronic change; nucleotide highly conserved across multiple species and three or more
splice prediction tools return >10 % difference in splice site prediction value between wild type and variant
3 Unknown significance
(VoUS)
1. Minor allele frequency <1 % in dbSNP (v142) and EVS (v6500) AND
2. Phenotype and inheritance pattern in patient correlates with the gene AND
3. Not described in the literature, or described in literature with inconclusive or no evidence AND
a) In silico predictions score variants as Class 4 but phenotype does not correlate with the gene OR
b) In silico predictions are conflicting (for example; conserved amino acid, very low MAF but Polyphen 2
and SIFT predict benign)
2 Unlikely to be
pathogenic
1. a) Minor allele frequency is between 1 % and 3 % in dbSNP (v142) and/or between 1 % and 3 % in EVS
(v6500) but phenotype and/or inheritance pattern in patient correlates with the gene OR
b) Minor allele frequency is <1 % in dbSNP and EVS but phenotype and/or inheritance pattern in patient does
not correlate with gene AND
2. a) Missense variant; amino acid is weakly conserved across multiple species and/or Polyphen 2 (HumVar)
and SIFT concur in predicting benign OR
b) Synonymous or intronic change; nucleotide weakly conserved across multiple species and splice prediction
toolsa show no significant difference between wild type and variant, even if MAF is <1 % on dbSNP and EVS AND
3. a) Some evidence for benign status in literature but weak or inconclusive AND/OR
b) Some evidence that variant does not segregate with disease in pedigree of patient(s) tested in this cohort
1 Clearly not
pathogenic
Frequency >3 % in dbSNP (v142) or >3 % in Exome Variant Server (v6500) OR
Frequency <3 % but described and proven as not pathogenic in published literature
aFive splice prediction tools queried via Alamut software interface: SpliceSite Finder Like, MaxEntScan, NNSplice, GeneSplicer, Human Splicing Finder
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Two genes, SH3TC2 and IGHMBP2, accounted for 62 %
of all recessive diagnoses (20/32 patients).
There was no significant difference in the overall diag-
nostic yield achieved between patients under 18 years of
age and those aged 18 and over (36/135 vs 102/313;
Fisher’s exact test value 0.222, p < 0.05).
The clinical and genetic heterogeneity of IPN has
always presented a challenge for the clinical classifica-
tion. Specialist clinics have played a significant role in
guiding the genetic testing. A positive diagnostic yield of
62.6 % in CMT patients attending specialist clinics was
reported by Murphy et al. [21] and 67 % by Saporta et al.
[22]. This proportion is reported to be significantly lower
at 37.7 % in patients that have not been assessed in
specialist clinics [21]. These figures include patients
positive for the PMP22 duplication. Our overall diag-
nostic yield of 31 % does not include PMP22 duplication
positive patients, as the majority of our patients are
referred to us for gene panel testing following a normal
result for PMP22 copy number in their local laboratories.
For our local patients, the pick-up rate was estimated to
Table 3 Diagnostic yield for each phenotypic group, mode
of inheritance and gene
Phenotype Inheritance Gene Patients














Tested 101 Diagnosed 41




















Tested 152 Diagnosed 54







Table 3 Diagnostic yield for each phenotypic group, mode
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Tested 25 Diagnosed 5
Mixed AD AARS 5
MPZ 1
X-L GJB1 2
Tested 22 Diagnosed 8





Tested 57 Diagnosed 5
Overall total 448 Diagnosed 137
Highlighted bold: gene not previously available for routine diagnostic testing
in UK
aGene not previously requested for IPN
bOnly part of the gene was previously available for testing
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be approximately 28 % (125/443) for the PMP22 duplica-
tion and 27 % (90/332) for the PMP22 deletion (patients
tested in a three year period 2007–2010, unpublished
data). This figure is slightly higher than the 20.9 % PMP22
CNVs identified by Murphy et al. [21] in those not attend-
ing a specialist inherited neuropathy clinic, and almost
twice the level seen in the cohort of DiVincenzo et al., at
14.5 % [23].
DiVincenzo et al. have reported the positive rate of mu-
tations in 14 genes (PMP22, GJB1, MPZ, MFN2, SH3TC2,
GDAP1, NEFL, LITAF, GARS, HSPB1, FIG4, EGR2, PRX
and RAB7A) in a very large cohort of 17,789 individuals
[23]. Among these patients, 4 genes accounted for 94.9 %
of positive results: PMP22, GJB1, MFN2, MPZ. Murphy
et al. also reported a 94 % pick up rate of those four genes,
including point mutations and rearrangements [21]. The
equivalent positive pick up rate in our patients, excluding
the rearrangements is 43.4 % (we have 36 positive patients
in the four genes versus 83 positive in the 14 genes). This
possibly reflects the fact that in this first year that the gene
panel was available, a significant proportion of the patients
referred for testing had already undergone testing for
these common genes, and only those without a mutation
were referred to us for further testing on the NGS panel.
Copy number variation
Copy number variation (CNV) is considered rare except
for the common 17p11.2 PMP22 copy number variants,
and accounts for about 1 % of diagnoses [24]. We
detected two patients with whole PMP22 gene duplica-
tion, and three patients with a whole gene deletion
(PMP22, GJB1, SLC12A6). We also detected one patient
homozygous for GAN exon 1 deletion and one com-
pound heterozygous for a partial deletion of the SBF2
gene encompassing exons 14 to 27.
Our existing pipeline is set up to detect whole gene de-
letions and duplications; for smaller CNVs we currently
manually check the data. However, it has been proven
particularly useful to have this ability to check for CNVs
in the cases where one pathogenic variant was detected in
a gene associated with recessive inheritance.
The PMP22 c.353C > T, p.(Thr118Met) variant
We detected the PMP22 c.353C > T, p.(Thr118Met) vari-
ant in five patients (patients 1–5, Table 4). This variant
has been widely documented; however its pathogenicity
has been controversial in the literature [25–27]. The
latest evidence suggested that it is associated with neur-
opathy, albeit with reduced penetrance [28]. This variant
is present in dbSNP (rs104894619) with a minor allele
frequency (MAF) of 0.08 %, in the Exome Variant Server
with a MAF of 0.53 % (European-American cohort) and
in the ExAC browser with MAF 0.73 % (European non-
Finnish, including one homozygote). Four out of five of
our patients had another class 4 or 5 variant and only
one patient had no other variants.
The diversity of the phenotypes in our patients with the
c.353C > T, p.(Thr118Met) PMP22 variant, the variant’s
co-existence with pathogenic mutations in other genes
and its high MAF in the general population, challenge it
being a causative variant, although its contribution to a
phenotype cannot be excluded.
The MFN2 c.1403G > A, p.(Arg468His) variant
This variant was detected in three patients (patients 6–8,
Table 4). The c.1403G > A, p.(Arg468His) variant is
recorded on dbSNP (rs138382758) with MAF 0.20 %, on
the Exome Variant Server with MAF 0.24 % (European-
American cohort) and in the ExAC with MAF 0.32 %
(European, non-Finnish cohort) including two homozy-
gotes. It was originally reported by Engelfried K et al. in
a patient with distal weakness and atrophy of the legs
and also her symptomatic father, but as it was also de-
tected on one allele in the population study (260 chromo-
somes), it was considered to be a benign polymorphism
[29]. In a later study by Casasnovas et al. the variant
c.1403G >A, p.(Arg468His) was identified in six of 14
unrelated Spanish families presenting mild or moderate
CMT2, with dominant inheritance and onset of disease in
the third to fifth decade [30]. Functional studies were
conducted on fibroblasts from a skin biopsy and it was
demonstrated that this variant decreased efficiency of
ATP synthesis leading to decreased ATP production; this
supported the pathogenicity of this variant. The authors
suggested that the anonymous control subject identified
by Engelfried et al. could be a CMT2 patient who had not
yet reached the age of onset of symptoms. Braathen et al.
described a patient with CMT1 (reduced NCVs) present-
ing at age 2, who had the MFN2 c.1403G >A variant,
suggesting that it may also associate with demyelinating
CMT [31]. The presence of this variant was consistent
with axonal phenotype in two of our patients while the
third presented with early onset CMT1, matching the
patient described by Braathen et al.
Broadening the phenotypic spectrum associated with
specific genes
A total of six patients were found to have pathogenic
variants in genes that would not have been traditionally
tested for their phenotype (patients 8–14, Table 4). Two
patients referred as having CMT1 were found to have
pathogenic variants in MFN2. Two patients referred
with axonal neuropathy were found to have a PMP22
variant; one of them the classical PMP22 deletion and
the other the PMP22 duplication. A patient referred with
HMN was also found to have a likely pathogenic variant
in PMP22, and was carrier of a recessive pathogenic
variant in MED25. A patient with CMT1 was found to
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have the recurrent pathogenic variant in AARS. Our IPN
multigene testing is an unbiased approach; these patients
would have not received a diagnosis based on the phe-
notypically - led genetic testing, either by the traditional
sequential testing or by CMT phenotype-specific panels.
A few of these patients might have been misclassified in
the local clinic, without the benefit of specialist expertise
at a regional or national centre; however the NGS panel
approach for genetic diagnosis can help to compensate
for limited access to specialist diagnostic expertise.
Identification of multiple genetic causes
Four adult patients were found to have potentially more
than one causative variant in different genes (patients 15–
17, Table 4). One patient with atypical CMT and known to
have the PMP22 duplication was found to have the known
pathogenic variant in SH3TC2, c.505 T > C p.(Tyr169His).
This patient had also one variant of unknown clinical
significance in MFN2, c.1936G >A, p.(Val646Ile). Another
adult patient with axonal neuropathy was found to have
the SH3TC2 c.505 T > C, p.(Tyr169His) variant along-
side a likely pathogenic (predicted truncating) variant
in GDAP1, c.501dupA, p.(Glu168Argfs*3). While homo-
zygous or compound heterozygous pathogenic variants
in SH3TC2 are associated with autosomal recessive
CMT4C, there is growing evidence that heterozygosity for
some SH3TC2 variants can cause axonal neuropathy.
Lupski et al. identified the p.(Tyr169His) variant in the
heterozygous state in a parent and a grandparent of the
proband [4]. The p.(Tyr169His) heterozygotes did not
have CMT1, but were found to have patchy axonal poly-
neuropathy with definite median-nerve mononeuropathy
Table 4 Interesting patients; examples to highlight the added value of gene panel testing
Patient Phenotype Gene and RefSeq Transcript Variant Pathogenicity class Reference
1 CMT2 PMP22 NM_000304.2 c.353C > T p.(Thr118Met) C5 [25–28]
GJB1 NM_000166.5 c.-17G > A p.? C5 [35]
2 CMT2 PMP22 NM_000304.2 c.353C > T p.(Thr118Met) C5 [25–28]
PMP22 NM_000304.2 c.281delG p.(Gly94Alafs*17) C5 [36–38]
3 HMN PMP22 NM_000304.2 c.353C > T p.(Thr118Met) C5 [25–28]
REEP1 NM_001164730.1 c.*50G > A p.? C5 [39]
DYNC1H1 NM_001376.4 c.3500 T > A p.(Val1167Glu) C4 This study
4 HMN PMP22 NM_000304.2 c.353C > T p.(Thr118Met) C5 [25–28]
GARS NM_002047.2 c.485A > G p.(His162Arg) C4 This study
5 HSN PMP22 NM_000304.2 c.353C > T p.(Thr118Met) C5 [25–28]
6 CMT2 MFN2 NM_014874.3 c.1403G > A p.(Arg468His) C5 [29–31]
MFN2 NM_014874.3 c.809 T > C p.(Met270Thr) C3 This study
MFN2 NM_014874.3 c.1029_1032delGAG p.(Arg344del) C3 This study
7 HMN MFN2 NM_014874.3 c.1403G > A p.(Arg468His) C5 [29–31]
8 CMT1 MFN2 NM_014874.3 c.1403G > A p.(Arg468His) C5 [29–31]
9 CMT1 MFN2 NM_014874.3 c.2119A > G p.(Arg707Trp) C5 [31]
10 CMT2 PMP22 NM_000304.2 c.448G > C p.(Gly150Arg) C4 This study
11 CMT2 PMP22 NM_000304.2 c.(?_-1)_(*1_?) del p.0 C5 [40]
12 CMT1 AARS NM_001605.2 c.986G > A p.(Arg329His) C5 [41]
13 HMN PMP22 NM_000304.2 c.185 T > G p.(Leu62Arg) C4 This study
MED25 NM_030973.3 c.1004C > T p.(Ala335Val) C5 [42]
14 CMT2 PMP22 NM_000304.2 c.(?_-1)_(*1_?) dup p.(=) dup C5 [43]
SCN9A NM_002977.3 c.3369G > T p.(Leu1123Phe) C4 This study
15 CMT complex PMP22 NM_000304.2 c.(?_-1)_(*1_?) dup p.(=) dup C5 [43]
SH3TC2 NM_024577.3 c.505 T > C p.(Tyr169His) C5 [4]
MFN2 NM_014874.3 c.1936G > A p.(Val646Ile) C3 This study
16 CMT2 SH3TC2 NM_024577.3 c.505 T > C p.(Tyr169His) C5 [4]
GDAP1 NM_018972.2 c.501dupA p.(Glu168Argfs*3) C4 This study
17 HSN RAB7 NM_004637.5 c.484G > A p.(Val162Met) C5 [32]
SPTLC2 NM_004863.3 c.1142 T > C p.(Phe381Ser) C4 This study
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at the wrist on neurophysiology. A patient referred
with CMT2 was found to have the PMP22 duplication
and a SCN9A likely pathogenic variant c.3369G > T,
p.(Leu1123Phe). Another patient presenting with HSN
was found to have the known RAB7A pathogenic variant
c.484G >A, p.(Val162Met) [32], and a likely pathogenic
variant in SPTLC2, c.1142 T > C, p.(Phe381Ser). These
results support the effectiveness of multi-gene testing,
since traditional or phenotype-led testing would not have
picked up these variants, and have implications for recur-
rence risk and genetic counselling.
Focused genetic testing has been supported as an
approach to provide diagnosis either in the form of small
panels or as a tiered approach, by exclusion of variants
in common genes before proceeding to NGS testing.
The review and recommendations set out by Murphy
et al. and Saporta et al. provided essential guidance for
clinicians navigating a sea of individual genes in pursuit
of a genetic diagnosis [21, 22]. Elsewhere the approach
of CMT phenotype-specific panel testing has been pro-
posed for CMT diagnosis as a means to avoid high cost
and difficulty in result interpretation [33]. In our experi-
ence NGS is efficient and removes the need for serial
gene sequencing in most cases. Testing specific genes
according to phenotype association may be beneficial if
the patients have a very definite neuropathy subtype and
are referred from expert neurology clinics; for example
GJB1 in a clearly X-linked pedigree, or PMP22 in HNPP.
The cost of design and validation for one large panel is
significantly lower than the sum costs of multiple
smaller panels. The challenge of variant interpretation
should not be underestimated; however prioritisation of
variants according to phenotypic compatibility, and the
use of in silico tools and public databases has proven to
be an efficient approach. By incorporating all 56 genes
in one assay, we revealed mutations in genes that would
have not emerged had we been limited to a phenotype-
derived subset of genes. Other authors have also recently
been advocating the benefits of expanded multi-gene
testing. Hoyer et al. have reported findings similar to
ours, including detection of dual pathology and CMT1
patients with MFN2 mutations [34].
Conclusions
We developed a 56-gene IPN NGS targeted panel assay
as a specialist UK Genetic Testing Network service. This
is a frontline diagnostic tool and has largely replaced
single-gene Sanger sequencing. Testing was completed
for 448 patients in the first 18 months post launch.
Genetic diagnosis was achieved in 137 patients (31 %).
Testing revealed high heterogeneity, dual pathology and
less-tight phenotype-genotype associations.
Assessment and classification of variants is currently a
time consuming process, however this task becomes easier
as the tools improve and the databases expand. Detailed
clinical information is advantageous for variant interpret-
ation, nonetheless we have highlighted cases that would
not have achieved a diagnosis had the phenotype been
used to guide gene selection.
Clinical-exome or whole-exome sequencing may be
appropriate for patients in whom no pathogenic variant
is detected on the NGS panel. However, the diagnostic
yield achieved at this stage does not support sequencing
the exome immediately, despite comparable cost, due to
the complexity of analysis of larger data sets. This targeted
panel approach has the advantage of producing smaller
data sets than exome or genome sequencing, but simul-
taneously it overcomes the limitation imposed by basing
testing decisions on the limited genotype-phenotype data
available for the rare genes. It facilitates the testing of
category-equivocal cases where the patients do not fit in a
particular phenotypic subgroup. It is an efficient approach
from the perspective of an accredited diagnostic labora-
tory, as only one assay needs to be validated. Redesign of
the panel is relatively straightforward, allowing inclusion
of genes newly identified in IPN pedigrees. Genes with
very recently established clinical associations tend not to
feature on commercial clinical exome panels which are
updated infrequently.
The clinical and genetic heterogeneity of IPN makes
both diagnosis and genetic counselling quite challenging
[21]. The benefits of obtaining a genetic diagnosis include
provision of a definite clinical classification (including
clarification of equivocal cases) and guidance on progno-
sis. Furthermore, accurate genetic risk assessment and
cascade testing is beneficial not only for the patient but
also for their family. As clinical trials progress for some
types of CMT, genotyping will be essential. Advances in
sequencing technology have made it time and cost effective
to screen large numbers of causative genes simultaneously.
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